A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis
UCB Biopharma SRL
392 participants
Dec 10, 2025
INTERVENTIONAL
Conditions
Summary
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will receive bimekizumab (BKZ) at pre-specified time points.
Participants will receive bimekizumab (BKZ) at pre-specified time points.
Participants will receive bimekizumab (BKZ) at pre-specified time points.
Locations(63)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07290036